Coherus Biosciences (CHRS) AI Stock Analysis

• Market Cap: $88.80M
• Dividend Yield: N/A
• Average Volume (3M): 1.44M
• Price to Earnings (P/E): 5.5
• Beta (1Y): 1.33
• Revenue Growth: -34.58%
• EPS Growth: -62.19%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 115,933,270
• 10 Day Avg. Volume: 833,545
• 30 Day Avg. Volume: 1,444,644
• PEG Ratio: <0.01
• Price to Book (P/B): -0.48
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 175.31
• Enterprise Value/Market Cap: 2.67
• Enterprise Value/Revenue: 0.22
• Enterprise Value/Gross Profit: 2.16
• Enterprise Value/Ebitda: -0.56
• 1Y Price Target: $5.02
• Price Target Upside: 527.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 45 Neutral
• Price Target: $1.00 ▲(25.00%Upside)

The overall stock score reflects significant financial challenges, including declining revenues and high leverage, which are major risk factors. While there are promising growth prospects from the oncology focus and recent corporate events, the technical analysis indicates bearish trends. The valuation remains unattractive due to negative earnings and lack of dividends. Strategic initiatives and cost-saving measures offer some positive outlook, but financial stability and market penetration remain crucial.

Positive Factors

Innovation Potential

The partial response in a heavily pretreated PD-1 refractory patient is an achievement, representing the potential of CHS-114 to potentially overcome PD-1 resistance.

Regulatory Momentum

The National Comprehensive Cancer Network (NCCN) revised guidelines include Loqtorzi as the preferred regimen.

Strategic Transition

Coherus has made significant positive progress as it has completed its transition to a novel oncology company, including what is considered an attractive sale of its biosimilar business, allowing the company to extinguish its debt and provide funding for the next ~18 months as it executes on driving Loqtorzi sales.

Negative Factors

Financial Performance

Q1 net revenue of $40MM was below our $55MM forecast.

Market Competition

Checkpoint inhibitors remain a crowded space dominated by some of the largest players in pharma, and Coherus' pipeline assets to pair with the PD1 are relatively early stage.

Revenue Growth Concerns

Sales of $7.3M in 1Q are expected to be greeted with disappointment by investors.

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus BioSciences, Inc. (CHRS) is a commercial-stage biopharmaceutical company focused on developing and commercializing biosimilar and innovative therapeutics. The company operates primarily in the healthcare sector, aiming to increase patient access to essential biologics. Coherus' core products include biosimilars for oncology and immunology treatments, offering more affordable options compared to branded biologics.

How the Company Makes Money

Coherus BioSciences generates revenue primarily through the sale of its biosimilar products. The company's revenue model involves the development, manufacturing, and commercialization of biosimilars, which are essentially equivalent versions of existing biologic drugs that have lost patent protection. Key revenue streams include direct sales of these biosimilars to healthcare providers and distributors. Coherus also enters into strategic partnerships with other pharmaceutical companies to enhance its market reach and distribution capabilities, thereby contributing to its earnings. As patents of various branded biologics expire, Coherus capitalizes on these opportunities by introducing cost-effective biosimilar alternatives, thus driving its revenue growth.

Coherus Biosciences Financial Statement Overview

Summary

Coherus Biosciences is facing significant financial challenges, with declining revenues, persistent net losses, and high leverage. The negative equity position and reliance on external financing highlight potential risks and financial instability.

Income Statement

The income statement reveals significant challenges for Coherus Biosciences, with declining revenue and consistent net losses over the periods. The TTM data shows negative margins across gross profit, EBIT, and EBITDA, indicating profitability issues. Revenue growth is negative, reflecting a downward trend in sales.

Balance Sheet

The balance sheet indicates high financial leverage with a negative stockholders' equity, suggesting insolvency risks. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio is negative, underscoring financial instability. Overall, the balance sheet reflects potential risks due to high liabilities.

Cash Flow

Cash flow analysis shows limited operational cash generation with a marginally positive free cash flow in the TTM period. However, historical data reflects negative operating and free cash flows, indicating reliance on external financing. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash conversion.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
197.50M	266.96M	257.24M	211.04M	326.55M	475.82M
	Gross Profit
109.66M	149.41M	94.46M	140.96M	268.96M	438.16M
	EBIT
-114.58M	-111.67M	-203.20M	-256.88M	-263.86M	156.32M
	EBITDA
-98.76M	60.94M	-193.94M	-255.58M	-260.69M	161.84M
	Net Income Common Stockholders
-130.94M	28.51M	-237.89M	-326.63M	-306.32M	132.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
125.99M	125.99M	117.75M	191.68M	417.19M	541.16M
	Total Assets
448.53M	448.53M	629.60M	480.85M	679.33M	841.65M
	Total Debt
269.90M	269.90M	480.84M	471.06M	408.28M	404.02M
	Net Debt
143.92M	143.92M	377.95M	407.51M	-8.91M	-137.13M
	Total Liabilities
580.52M	580.52M	823.03M	618.26M	581.61M	560.67M
	Stockholders Equity
-131.99M	-131.99M	-193.43M	-137.42M	97.73M	280.97M
Cash Flow		Free Cash Flow
500.00K	-20.44M	-175.17M	-243.16M	-38.72M	147.09M
	Operating Cash Flow
500.00K	-20.44M	-174.88M	-241.12M	-37.43M	154.15M
	Investing Cash Flow
10.07M	230.32M	144.64M	-166.85M	-138.41M	-14.40M
	Financing Cash Flow
-188.13M	-186.97M	69.60M	54.33M	51.88M	223.95M

Coherus Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.90, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.13 is Neutral, neither overbought nor oversold. The STOCH value of 49.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CHRS.

Coherus Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.25B	3.24	-45.38%	2.81%	16.79%	-0.06%
CHRS	45 Neutral	$88.80M	5.55	0.51%	―	-34.58%	-62.19%
SLS	43 Neutral	$157.65M	―	-144.90%	―	―	60.51%
NAUT	41 Neutral	$96.86M	―	-30.93%	―	―	-1.20%
TIL	34 Underperform	$196.14M	―	-44.50%	―	―	52.54%
GNLX	33 Underperform	$96.98M	―	-131.36%	―	-100.00%	9.16%

Coherus Biosciences Corporate Events

Coherus Biosciences Rebrands to Coherus Oncology

On May 29, 2025, Coherus BioSciences, Inc. changed its name to Coherus Oncology, Inc. to better align with its focus on innovative cancer therapeutics. This strategic transformation underscores the company’s commitment to advancing its oncology pipeline, including FDA-approved treatments and promising candidates in clinical trials, aiming to set new standards in cancer care and improve patient outcomes.

The most recent analyst rating on (CHRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Coherus Biosciences Board Member Stolper Steps Down

On April 22, 2025, Mark D. Stolper, a member of the Board of Directors at Coherus BioSciences, announced his decision not to stand for re-election at the company’s 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company, and he will continue to serve in a consulting role until the end of 2026. Following his decision, the board will reduce its size to nine directors. To ensure balanced representation among the board’s classes, on April 23, 2025, Rita A. Karachun and Michael Ryan were reclassified to different board classes, maintaining uninterrupted service while complying with the company’s Certificate of Incorporation.

Coherus Biosciences CCO Resigns After UDENYCA Divestiture

Paul Reider, Coherus BioSciences’ Chief Commercial Officer, resigned effective April 30, 2025, following the company’s divestiture of its UDENYCA franchise. His departure is amicable, with no disagreements cited, and he will receive a compensation package including salary continuation and stock option extensions, while advising the company part-time until April 2026.

Coherus Biosciences Completes UDENYCA Franchise Divestiture

On April 14, 2025, Coherus BioSciences announced the completion of its UDENYCA franchise divestiture to Intas Pharmaceuticals for up to $558.4 million. This strategic move, which included an upfront payment of $483.4 million, allows Coherus to focus on its oncology programs, reduce debt, and extend its cash runway into 2027, thereby strengthening its market position and operational focus on novel cancer therapies.